Non-Hormonal Contraceptives Market Report 2025

The non-hormonal contraceptives market size has grown strongly in recent years. It will grow from $23.73 billion in 2024 to $25.47 billion in 2025 at a compound annual growth rate (CAGR) of 7.3%. The growth during the historic period can be credited to increasing support for women’s health initiatives, the expanding availability of over-the-counter non-hormonal contraceptive options, a heightened focus on developing male contraceptive products, rising demand for fertility-awareness-based contraceptive methods, and a growing number of product approvals and launches within the non-hormonal contraceptive market.

The non-hormonal contraceptives market size is expected to see strong growth in the next few years. It will grow to $33.48 billion in 2029 at a compound annual growth rate (CAGR) of 7.1%. The growth expected in the forecast period is driven by rising demand for hormone-free birth control options, increased awareness of side effects linked to hormonal contraceptives, a growing preference for natural and chemical-free methods, the increasing prevalence of sexually transmitted infections, and heightened health consciousness among women about reproductive health. Key trends during this time include advancements in biomaterials for non-hormonal contraceptive devices, technological innovations in barrier contraceptive designs, the incorporation of smart tracking features with fertility-awareness techniques, progress in drug-free contraceptive gels and films, and the development of technology-enabled self-administration tools for contraceptive devices.

The rising prevalence of sexually transmitted diseases is expected to drive growth in the non-hormonal contraceptives market in the future. Sexually transmitted diseases (STDs) are infections primarily spread through sexual contact and caused by bacteria, viruses, or parasites. The increase in STDs is largely due to a decrease in condom use, which raises the risk of infection during unprotected sex. Non-hormonal contraceptives, such as male and female condoms, act as a physical barrier that prevents the exchange of bodily fluids during sexual activity, helping to reduce the transmission of STDs. For example, in April 2025, the Minnesota Department of Health (MDH), a US state health agency, reported that the proportion of HIV cases among males aged 35 to 39 rose from 10% in 2023 to 17% in 2024. Thus, the growing prevalence of sexually transmitted diseases is contributing to the expansion of the non-hormonal contraceptives market.

Companies in the non-hormonal contraceptives market are focusing on innovative delivery systems such as preloaded intrauterine device (IUD) delivery systems to make insertion easier, increase user convenience, and improve clinical efficiency. A preloaded IUD delivery system combines the device and its inserter into a single, ready-to-use unit designed to simplify the insertion process, reduce setup time, and lower the risk of contamination or handling errors. For instance, in September 2024, CooperSurgical Inc., a US-based medical device and fertility company, launched the Paragard Single-Handed Inserter, which aims to improve insertion efficiency and patient comfort during non-hormonal IUD placement. The device provides over 99% effective, long-term birth control for up to 10 years by preventing sperm from fertilizing an egg. It offers immediate, reversible contraception without hormones and requires low maintenance after insertion.

In July 2022, Organon International, a US pharmaceutical company, partnered with Cirqle Biomedical Contraception ApS to develop and commercialize an innovative, non-hormonal, on-demand contraceptive. This collaboration aims to expand contraceptive options and address unmet needs in women’s health. Cirqle Biomedical Contraception ApS is a Denmark-based life sciences company focused on creating non-hormonal contraceptive solutions for women.

Major players in the non-hormonal contraceptives market are Bayer AG., Church & Dwight Co., Mankind Pharma Limited, Okamoto Industries, CooperSurgical Inc., PSI India Pvt Ltd., Karex Berhad, Natural Cycles Nordic AB, Fuji Latex Co. Ltd., PREGNA INTERNATIONAL LTD., Cupid Limited, Veru Inc., Evofem Biosciences Inc., Daré Bioscience Inc., Global Protection Corp., SMB Corporation of India, HLL Lifecare Limited, YourChoice Therapeutics Inc., Cirqle Biomedical Contraception ApS, Eppin Pharma Inc., Contraline Inc., and Linepharma International Ltd.

North America was the largest region in the non-hormonal contraceptives market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in non-hormonal contraceptives report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the non-hormonal contraceptives market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The non-hormonal contraceptives market consists of sales of male condoms, copper intrauterine devices (IUDs), diaphragms, cervical caps, and spermicides. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The non-hormonal contraceptives market research report is one of a series of new reports that provides non-hormonal contraceptives market statistics, including non-hormonal contraceptives global market size, regional shares, competitors with non-hormonal contraceptives market share, detailed non-hormonal contraceptives market segments, market trends and opportunities, and any further data you may need to thrive in the non-hormonal contraceptives industry. The non-hormonal contraceptives market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Non-hormonal contraceptives are methods used to prevent pregnancy without involving hormones that alter a woman’s reproductive system. These contraceptives work by using physical barriers, chemical agents, or natural tracking techniques that do not interfere with the body’s hormonal balance.

The primary categories of non-hormonal contraceptives include devices, sterilization, and others. Devices are physical tools or instruments designed to carry out specific functions, often applied in medical, industrial, or consumer settings. Their mechanisms may involve acting as antagonists, agonists, inhibitors, or modulators. These products can be administered via various routes such as intramuscular, intravaginal, intravenous, oral, subcutaneous, topical, transdermal, and more. Their therapeutic purposes cover both disease treatment and symptom relief. The target conditions for these contraceptives include bacterial vaginosis, contraception, endometriosis, postmenopausal osteoporosis, uterine fibroids, vaginitis, among others.

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.